NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,...
Kits Available in July for DistributionLondon, United Kingdom, July 26, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or...
BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company,...
Data from the recent 0.19 mg FAc implant Phase 4 observational real-world study were presented at the annual American Society...
Building on a Successful Pilot Study, the Two Companies are Further Validating the Link Between Gut Health and HappinessSAN DIEGO...
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected...
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
VANCOUVER, British Columbia, July 26, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC,...
Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic’s platform while expanding footprint to San...
TORONTO, July 26, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
The Company's Proprietary Hydrogel Technology Protects Lower Lashes and Allows for Gentle Removal LANGHORNE, Pa., July 26, 2022 (GLOBE NEWSWIRE)...
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline...
DALLAS, July 26, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented...
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022JENA, Germany, July 26,...